Por favor, tente outra pesquisa
O objectivo do Subfundo consiste em alcançar crescimento de capital a longo prazo. O Gestor de Investimento procurará alcançar os objectivos do Subfundo investindo permanentemente pelo menos dois terços do total de activos do Subfundo em acções e instrumentos associados a acções emitidas por sociedades envolvidas em produtos e serviços médicos e de cuidados de saúde em todo o mundo. Os investimentos serão efectuados em produtores farmacêuticos, firmas biotecnológicas, fabricantes de dispositivos e instrumentos médicos, distribuidores de produtos de saúde, prestadores e gestores de cuidados e outras sociedades de serviços de cuidados de saúde.
Nome | Título | Desde | Até |
---|---|---|---|
Gregg Bridger | - | 2023 | Agora |
Biografia | Gregg Bridger is a fund manager in the global equities team. Prior to joining FOUR, he was employed as a Product Specialist in the Fundamental equities team at Goldman Sachs Asset Management. Previously, Gregg was an assistant portfolio manager in the emerging markets equity team at Credit Suisse. Gregg holds a BA (Hons) in Economics from the University of Leicester and is a CFA Charterholder. | ||
Stephen Kelly | Portfolio Manager | 2023 | Agora |
Biografia | Stephen graduated from the University of Exeter in 1990 with an honours degree in Economics. He joined Olliff & Partners as a trainee in the equity research department where he covered the UK paper and packaging sector. In February 1992 he joined the US Desk at Capel Cure Myers as an assistant Fund Manager and in December 1995 was promoted to Fund Manager.Stephen joined Framlington in 1997 as a Fund Manager on the US Desk responsible for the US and technology. | ||
Stephen Kelly | Portfolio Manager | 2021 | 2023 |
Biografia | Stephen graduated from the University of Exeter in 1990 with an honours degree in Economics. He joined Olliff & Partners as a trainee in the equity research department where he covered the UK paper and packaging sector. In February 1992 he joined the US Desk at Capel Cure Myers as an assistant Fund Manager and in December 1995 was promoted to Fund Manager.Stephen joined Framlington in 1997 as a Fund Manager on the US Desk responsible for the US and technology. | ||
Peter Hughes | Portfolio Manager | 2021 | 2023 |
Biografia | Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News. | ||
Linden Thomson | - | 2015 | 2021 |
Dani Saurymper | - | 2015 | 2021 |
Biografia | Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare. | ||
Peter Hughes | Portfolio Manager | 2007 | 2021 |
Biografia | Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News. | ||
Gemma Game | - | 2009 | 2015 |
Deane Donnigan | clinical Specialist | 2007 | 2008 |
Biografia | Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen. |
Quer mesmo bloquear %USER_NAME%?
Se o fizer, não poderá consultar as mensagens de %USER_NAME% e vice versa em Investing.com.
Adicionou %USER_NAME% com sucesso à sua Lista de Bloqueios
Uma vez que acabou de desbloquear esta pessoa, deve aguardar 48 horas antes de bloqueá-la novamente.
Diga-nos o que achou deste comentário
Obrigado!
Seu comentário foi enviado aos moderadores para revisão